ReviewEuropean respiratory review : an official journal of the European Respiratory Society2022
Holy Grail: the journey towards disease modification in asthma.
Review in European respiratory review : an official journal of the European Respiratory Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- A Systematic Review on Disease-Modifying Therapies in Parkinsonian Disorders.Clinical pharmacology and therapeutics · 2026Pooled it
- Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Trial
- [Asthma Management and Control in Germany in Light of Current Guidelines].Pneumologie (Stuttgart, Germany) · 2026Article
- Add-on mepolizumab in patients with severe asthma on medium-dose inhaled corticosteroids.ERJ open research · 2026Article
- Maternal 12-HETE is associated with childhood asthma and the responses to prenatal omega-3 supplementation.Cell reports. Medicine · 2026Article
- Evaluation of the concordance of asthma remission definitions according to international guidelines in a cohort of patients treated with monoclonal antibodies for severe asthma.Frontiers in pharmacology · 2026Article
- Effect of bronchial thermoplasty on airway inflammatory and profibrotic gene expression after one-year follow-up in severe asthma.Frontiers in immunology · 2026Article
- SerpinB1 reduces neutrophil airway inflammation, airway remodeling, and pyroptosis in asthmatic mice by interacting with Elane.Human cell · 2025Article
- High-Dimensional Analysis of Type 2 Lymphocyte Dynamics During Mepolizumab or Dupilumab Treatment in Severe Asthma.Allergy · 2025Article
- Article
- Type 2 gene expression signature in severe asthma associates with more advanced airway remodeling.Clinical and translational allergy · 2025Article
- Patient response and remission in respiratory disease: Special focus on severe asthma and chronic obstructive pulmonary disease.The Journal of international medical research · 2025Review
- Changes in Small Airway Physiology Measured by Impulse Oscillometry in Subjects with Allergic Asthma Following Methacholine and Inhaled Allergen Challenge.Journal of clinical medicine · 2025Article
- New Therapeutics for Heart Failure Worsening: Focus on Vericiguat.Journal of clinical medicine · 2024Review
- Beyond type 2 asthma biomarkers: risk stratification for NSAID-exacerbated respiratory disease.ERJ open research · 2024Article
- CDC167 exhibits potential as a biomarker for airway inflammation in asthma.Mammalian genome : official journal of the International Mammalian Genome Society · 2024Article
- Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab.Biomedicines · 2024Article
- Multidisciplinary Decision-Making-ITAlian Consensus After Two Years of Real Practice on the Management of Severe Uncontrolled CRSwNP by Biologics (ITACA Study).Current allergy and asthma reports · 2024Review
- Itaconate as a key regulator of respiratory disease.Clinical and experimental immunology · 2024Review
- Disease Modification in Asthma: Are We on the Right Way? A Multidisciplinary Expert Delphi Consensus (MODIASTHMA Consensus).Journal of asthma and allergy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
At present, there is no cure for asthma, and treatment typically involves therapies that prevent or reduce asthma symptoms, without modifying the underlying disease. A "disease-modifying" treatment can be classed as able to address the pathogenesis of a disease, preventing progression or leading to a long-term reduction in symptoms. Such therapies have been investigated and approved in other indications,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.